Report of the AI Pathology Task Force, Non-clinical Evaluation Expert          Committee, Japan Pharmaceutical Manufacturers Association: an overview of recent          publications about AI pathology

Emi Tomikawa; Satoshi Sakai; Yoshinori Yamagiwa; Yumi Kangawa; Yusuke Kagawa; Yuki Kato; Kensuke Kojima; Akira Inomata; Izumi Matsumoto; Gen Sato; Mutsumi Suzuki

doi:10.1293/tox.2024-0100

Review

Report of the AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Japan Pharmaceutical Manufacturers Association: an overview of recent publications about AI pathology

Emi Tomikawa, Satoshi Sakai, Yoshinori Yamagiwa, Yumi Kangawa, Yusuke Kagawa, Yuki Kato, Kensuke Kojima, Akira Inomata, Izumi Matsumoto, Gen Sato, Mutsumi Suzuki

Author information

Emi Tomikawa
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Toray Industries, Inc., 6-10-1 Tebiro, Kamakura-shi, Kanagawa 248-8555, Japan
Satoshi Sakai
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, Shizuoka 410-2321, Japan
Yoshinori Yamagiwa
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Senju Pharmaceutical Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
Yumi Kangawa
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Nippon Boehringer Ingelheim Co., Ltd., 6-7-5 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
Yusuke Kagawa
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Novartis Pharma K.K., 1-23-1 Toranomon, Minato-ku, Tokyo 105-6333, Japan
Yuki Kato
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Shionogi & Co., Ltd., 3-3-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan
Kensuke Kojima
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Kyowa Kirin Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan
Akira Inomata
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
FUJIFILM Toyama Chemical Co., Ltd., 4-1 Shimookui 2-chome, Toyama 930-8508, Japan
Izumi Matsumoto
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan
Gen Sato
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan
Mutsumi Suzuki
AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Kyowa Kirin Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan

Keywords: artificial intelligence, non-clinical, literature survey, digital pathology, experimental animals, image analysis

JOURNAL OPEN ACCESS

2025 Volume 38 Issue 3 Pages 191-198

DOI https://doi.org/10.1293/tox.2024-0100

Browse “Advance online publication” version

Details

Abstract

The use of artificial intelligence (AI) in non-clinical pathology is rapidly expanding. In this study, we conducted a literature survey of articles published after 2017 that used AI to analyze the histopathological images of experimental animals. We identified 44 articles that used AI for various purposes, including the detection of abnormal sites, determination and quantification of normal tissues, and classification of normal/abnormal images. AI systems or applications were either custom-built, commercially available, or a combination of both. Rats and mice were mainly used, and the liver was the most frequently analyzed organ. Our findings suggest that AI can be useful in non-clinical pathology and that collaboration between pharmaceutical companies or cooperation with IT experts can be a potential approach to further advance the utilization of AI in this field.

Corresponding author

Register with J-STAGE for free!